This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Los Angeles,
California90095

Purpose:

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer
cells. Biomed 101 may protect normal cells from the side effects of interleukin-2.
PURPOSE: Phase I trial to study the effectiveness of Biomed 101 in treating patients
receiving interleukin-2 for kidney cancer.

Study summary:

OBJECTIVES: I. Evaluate the safety and maximum tolerated dose of Biomed 101 in patients with
renal cell cancer currently treated with interleukin-2 (IL-2). II. Evaluate the effect of
different doses of Biomed 101 on the incidence and severity of IL-2 related toxicities and
on the incidence and frequency of IL-2 dose reduction due to IL-2 induced toxicity.
OUTLINE: This is a dose escalation study of Biomed 101. Patients receive oral Biomed 101
three times daily, followed by interleukin-2 IV on days 1-5 and 16-20. Cohorts of 5 patients
receive escalating doses of Biomed 101 until the maximum tolerated dose (MTD) is determined.
The MTD is defined as the dose preceding that at which at least 2 of 5 patients experience
dose limiting toxicities. Patients are followed for 1 month.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.